Presented by The Conference Forum in collaboration with the Society for Immunotherapy of Cancer
The Conference Forum is presenting the 2nd Immuno-Oncology 360°, a conference that combines business and clinical development strategies with scientific updates to prepare the market for accelerating immuno-oncology (IO) clinical trials. SITC Board of Directors President, Dr. Howard L. Kaufman, will participate as a speaker and panelist for the conference.
The science behind immune-based therapies is driving rapid change. With recent cancer immunotherapy drug development, breakthrough FDA approval status, and fast-tracking clinical trials, competition is fierce. Both small and large companies are racing to bring game-changing therapies to the market and in many cases, partnering to maximize on combination therapies. As a result, innovative approaches and developments are also creating increased momentum for investment/business development opportunities.
Designed by lead advisors Dr. Axel Hoos (GSK) and Dr. James Gully (NCI) along with support from Cancer Research Institute (CRI), Association for Cancer Immunotherapy (CIMT) and Society for Immunotherapy of Cancer (SITC), the 2nd annual Immuno-Oncology 360° event will enable attendees to obtain up-to-date information regarding business aspects, clinical advancements and scientific data that will help transform the way cancer is treated.
Non SITC members save 15% on their Immuno-Oncology 360° registration by using the discount code SITC15.
SITC members save 20% on their Immuno-Oncology 360° registration by using the discount code SITC20.
More information is available here.